Last update May 16, 2023



Safe substance and/or breastfeeding is the best option.

It is an analog of vecuronium, non-depolarizing muscle relaxant drug with a peripheral action, that is used as premedication for endotracheal intubation, general anesthesia and mechanical ventilation. Intravenous administration.

Since the last update we have not found published data on its excretion in breastmilk.

Its moderately elevated molecular weight and rapid half-life elimination period (about 15 minutes) make it highly unlikely that significant quantities will pass into breast milk. (Dalal 2014)

Also, its low oral bioavailability renders the pass of this agent to the infant's plasma highly unlikely.

Breastfed infants have not shown any problem after 1.5 to 5 hours of anesthesia time period with Rocuronio (additional drugs like Propofol, Remifentanil and Xenon were used). (Stuttmann 2010)

Rocuronium does not prevent a mother from breast feeding her baby shortly after recovering from anesthesia if she is awake and in good condition.

Experts authors consider the use of this medication to be probably compatible during breastfeeding. (Briggs 2015, Howie 2006)


We do not have alternatives for Rocuronium since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.


Rocuronium belongs to this group or family:


Main tradenames from several countries containing Rocuronium in its composition:


Variable Value Unit
Oral Bioavail. ≈ 0 %
Molecular weight 610 daltons
Protein Binding 30 %
VD 0.2 - 0.3 l/Kg
0.23 ± 0.04 hours


  1. Briggs GG, Freeman RK, Towers CV, Forinash AB. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Wolters Kluwer Health. Tenth edition (acces on line) 2015
  2. Dalal PG, Bosak J, Berlin C. Safety of the breast-feeding infant after maternal anesthesia. Paediatr Anaesth. 2014 Abstract
  3. Stuttmann R, Schäfer C, Hilbert P, Meyer MR, Maurer HH. The breast feeding mother and xenon anaesthesia: four case reports. Breast feeding and xenon anaesthesia. BMC Anesthesiol. 2010 Abstract Full text (link to original source) Full text (in our servers)
  4. Howie WO, McMullen PC. Breastfeeding problems following anesthetic administration. J Perinat Educ. 2006 Abstract Full text (link to original source) Full text (in our servers)
  5. Ferriols Lisart R,Ferriols Lisart F. Farmacología clínica y usos terapéuticos del Mivacurio. Farm Hosp. 1997 Full text (in our servers)

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM